オプションチェーンは、Tapinatorの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Tapinatorの市場センチメントを評価します。.

Tapinator (OTC:TAPM) 株価情報, オプションチェーン

Tapinator Inc develops and publishes category- leading apps for mobile platforms, with a focus on social casino games. The company's library includes more than 300 titles. It offers games such as Solitaire Derby, Crypto Trillionaire, Castlebuilder, Combo Quest, and Dice Mage 2 among others. The Company generates revenues from its mobile games via consumer transactions, including in-app purchases and subscriptions, and through the sale of branded advertisements.

Tapinator Inc

Aquestive Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two poster presentations highlighting results from the investigational use of Anaphylm&#x2122; (epinephrine) Sublingual Film in the treatment of severe allergic reactions, including anaphylaxis, will be presented at the Center for Food Allergy and Asthma Research (CFAAR) Food Allergy Summit , which will be held June 27-29 in Chicago, Ill. The data from these posters was originally presented at the 2025 AAAAI Annual Meeting. If approved by the U.S. Food and Drug Administration (FDA), Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.

News

AQST

Aquestive Highlights Oral Epinephrine Film for Severe Allergies at Upcoming Chicago Summit

GENI

Genius Sports Added To Russell 3000 Index, Effective June 30, As Part Of 2025 Russell Indexes Reconstitution

Needham analyst Gerald Pascarelli maintains Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Buy and lowers the price target from $215 to $195.

Price Target

Analyst Ratings

Needham Maintains Buy on Constellation Brands, Lowers Price Target to $195

GRMN

Garmin Expands FAA Data Comm Solution To Now Include Broad Retrofit Market With Over 25 Makes And Models Added To FAA Data Comm Participation List

HC Wainwright &amp; Co. analyst Robert Burns reiterates BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and maintains $138 price target.

Reiteration

BNTX

HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $138 Price Target

Dollar General Extends Red Cross Partnership With $250K Donation, Reinforcing $11M+ Legacy In Disaster Relief Support Nationwide

KGEI

Kolibri Expands Borrowing Base To $65M, Joins Russell 2000 Index, And Prepares New Lovina And Forguson Wells For July Output

Centrus Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) today announced that its wholly owned subsidiary, the American Centrifuge Operating, LLC, has produced and delivered 900 kilograms of High-Assay, Low-Enriched Uranium (HALEU) to the U.S. Department of Energy, reaching a critical milestone as the company pioneers first-of-a-kind HALEU production. With the successful production and delivery of the 900 kilograms,&nbsp;Centrus has achieved the production target for Phase II of its contract with the Department and to date has produced and delivered over 920 kilograms of HALEU to the Department under our contract with the Department.&nbsp;
Centrus now proceeds to HALEU enrichment production under Phase III of our contract with the Department.&nbsp; On June 20, 2025, Centrus announced that it had secured a contract extension from the Department for an additional year of production through June 30, 2026 as part of Phase III of the contract.&nbsp; Phase III includes options for up to eight years of additional production beyond June 30, 2026; these options are at the Department's sole discretion and subject to the availability of appropriations.
Centrus initiated its contract with the Department in 2019 and then continued in 2022 with a competitively-awarded, three-phase contract.&nbsp; Centrus finished Phase I in 2023 when it brought its cascade of advanced centrifuges into production in Piketon, Ohio, delivering an initial 20 kilograms of product to the Department.&nbsp; Phase II of the contract called for Centrus to produce 900 kilograms of HALEU by June 30, 2025.&nbsp;
The HALEU produced under this contract belongs to the Department and can be used to advance key national priorities like enabling the demonstration and commercialization of HALEU-fueled advanced reactors.

Centrus Energy's American Centrifuge Operating Produces And Delivers 900 Kilograms Of High-Assay, Low-Enriched Uranium To U.S. Department Of Energy

Santander Bank To Sell Seven Branches in Pennsylvania To Community Bank, N.A. Amid Strategic Digital-First Transformation

Community Bank To Acquire 7 Santander Branches In Allentown, Boosting Lehigh Valley Presence To 12 Locations With $600M In Deposits

Four in 10 Generation Z men admit they have passed off artificial intelligence-generated work as their own, according to a new Resume Genius survey that maps both the productivity gains and ethical risks the youngest employees bring to the office.
What Happened: The poll of 1,000 full-time Gen Z workers found 60% say AI lets them finish tasks faster and with less effort, while 56% believe it lifts accuracy. Yet nearly one-third overall, and 40% of men versus 20% of women, conceded they have used ChatGPT or similar tools to create assignments they later submitted as original work.
AI reliance also exacts a personal toll. Roughly 37% feel more replaceable at work, and 23% say the technology already hurts their mental health. One in five respondents believe they could no longer perform their jobs if AI were banned, and 39% report burnout from the constant stream of updates.
Rule-bending goes beyond faking deliverables. Almost a third of Gen Z workers acknowledged breaking company policy with AI, including sharing internal data, while 39% automate tasks without managerial approval. 
A separate Resume Genius research from March shows 46% of Gen Z hiring managers have already caught applicants cheating on skills tests with AI, highlighting what the firm calls a &#8220;growing integrity gap.&#8221;
See also: <a href="https://www.benzinga.com/markets/tech/25/06/46089330/bernie-sanders-slams-job-cuts-says-ai-should-give-workers-more-time-off-instead-of-throwing-you-out-on-the-street">Bernie Sanders Slams Job Cuts, Says AI Should Give Workers More Time Off: &#8216;Instead Of Throwing You Out On The Street&#8230;&#8217;</a>
Why It Matters: The findings echo another recent report that revealed Gen Z's enthusiasm for ChatGPT has <a href="https://www.benzinga.com/news/24/05/38635966/gen-z-misusing-ai-for-job-applications-as-employers-receive-hundreds-of-exact-same-cover-letters-wor">some employers worried</a> about carbon-copy résumés and cover letters. OpenAI chief Sam Altman recently predicted that software will soon handle <a href="https://www.benzinga.com/markets/tech/25/06/45809827/sam-altman-says-ai-can-replace-interns-but-gen-z-is-already-treating-it-like-a-work-buddy">many entry-level tasks</a>, even as young workers are already treating AI as a work buddy.
Still, experts say the generation's tech fluency remains an asset if channeled responsibly. Mark Cuban <a href="https://www.benzinga.com/news/25/03/44348044/mark-cuban-reveals-what-hed-do-as-a-gen-zer-to-get-ahead-even-while-sleeping-if-i-was-16-18-20-21-starting-today-i-would-spend-every-waking-minute-learning-it">advised Gen Z in March</a> to "spend every waking minute learning AI" to stay employable in a shifting economy. 
Yet Resume Genius career strategist Eva Chan warns in a statement <a href="https://retailtimes.co.uk/one-in-five-gen-z-workers-say-they-cant-do-their-job-without-ai/">shared</a> with Retail Times that outsourcing judgment to algorithms could leave young professionals unable to make decisions without "AI hand-holding."
Labor economists note Gen Z already <a href="https://www.benzinga.com/25/04/44756318/shaken-not-settled-gen-z-workers-lose-confidence-as-economic-clouds-gather">faces stagnant pay</a> and recession fears, which may fuel shortcuts.
Read next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46088840/phoebe-gates-shares-clever-chatgpt-hack-she-uses-almost-every-single-day-to-make-videos-for-her-fashion-tech-startup-the-internet-exists-for-a-reason">Phoebe Gates Shares Clever ChatGPT Hack She Uses &#8216;Almost Every Single Day&#8217; To Make Videos For Her Fashion-Tech Startup: &#8216;The Internet Exists For A Reason&#8217;</a></li>
</ul>
Image Via Shutterstock

Tech

Gen Z Leans On ChatGPT—But Nearly 1 In 3 Admit Breaking Company Rules, May Say They'd Flunk Without AI

Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) shares are trading higher in the <a href="https://www.benzinga.com/movers">premarket session on Wednesday</a>. This surge follows the company&#8217;s announcement that it has joined the NURTuRE-AKI consortium.
NURTuRE-AKI consortium is a collaboration aimed at developing an extensive patient database for acute kidney injury (AKI) <a href="https://www.benzinga.com/pressreleases/25/06/ac46087889/evotec-joins-nurture-aki-consortium-to-gain-multi-omics-based-molecular-understanding-of-acute-ki" target="_blank" rel="noreferrer noopener">research and therapeutic discovery</a>.
The initiative, known as NURTuRE-AKI, will help Evotec identify core biological mechanisms behind AKI and propel the discovery of novel treatment options.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44720573/kidney-disease-focused-vera-therapeutics-concludes-enrollment-in-pivotal-study-targets-2026-commercial-launch" rel="noreferrer noopener">Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch</a>
Evotec will integrate this data into its E.MPD platform, a molecular-level database that consolidates clinical and omics information, to enhance precision medicine capabilities.
By collecting longitudinal data across multiple stages of patient treatment, researchers will be able to evaluate disease progression with unprecedented depth and accuracy.
NURTuRE-AKI will focus on patients most vulnerable to AKI, including those undergoing cardiac surgery and individuals transitioning from acute kidney injury to chronic kidney disease.
The project will gather samples of blood, urine, DNA, and tissue alongside medical data, forming what is expected to be the most comprehensive AKI cohort worldwide.
&#8220;NURTuRE-AKI offers a rare opportunity to uncover molecular targets and develop biomarkers that could accelerate breakthroughs in kidney care,&#8221; said Cord Dohrmann, Chief Scientific Officer of Evotec.
He emphasized the company&#8217;s commitment to finding collaborators aligned with this mission.
Elaine Davies, Director of Research Operations at Kidney Research U.K., expressed optimism about the partnership, noting the initiative&#8217;s potential to reshape how kidney diseases are diagnosed and treated.
Price Action: EVO shares are trading higher by 3.19% to $4.210 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/partner/general/25/06/46057355/p3-reveals-how-data-is-solving-the-healthcare-crisis-for-seniors" target="_blank" rel="noreferrer noopener">P3 Reveals How Data Is Solving The Healthcare Crisis For Seniors</a></li>
</ul>
Photo via Shutterstock

Biotech

Equities

Health Care

Markets

Movers

General

Evotec's Collaboration Sparks Hope For Acute Kidney Injury Breakthroughs

The U.S. government has successfully tested a long-range radar detection system that could be utilized in President Donald Trump's ambitious <a href="https://www.benzinga.com/25/05/45548110/trumps-golden-dome-launches-new-era-for-defense-stocks-like-rtx-lockheed-martin-l3harris">Golden Dome missile defense system</a>.
What Happened: The Long Range Discrimination Radar, built by defense giant Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), successfully acquired, tracked and reported missile data during a test in Alaska's Clear Space Force Station, Reuters reported on Tuesday.
The report suggests that the LRDR is currently placed as part of the Ground-Based Midcourse Defense, designed to increase the efficacy of interceptors for missiles fired on the country by Iran or North Korea.
The system successfully tracked a target developed by the U.S. Missile Defense Agency over 1243 miles or 2,000 kilometers off the coast of Alaska, the report shared.
Why It Matters: The radar system could play a crucial role in Trump's Golden Dome, which will reportedly cost over $175 billion to develop, has already attracted a lot of attention from defense as well as tech companies.
SpaceX, as well as Peter Thiel's Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), have both reportedly <a href="https://www.benzinga.com/25/04/44861620/spacex-palantir-frontrunners-in-bid-that-could-build-donald-trumps-golden-dome-report">emerged as ‘frontrunners'</a> to secure key contracts within the initiative.
However, other companies like Lockheed Martin as well as Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) have also <a href="https://www.benzinga.com/markets/equities/25/06/45973965/boeing-lockheed-martin-compete-for-key-role-in-trumps-175-billion-golden-dome-project">joined the race </a>with Lockheed Martin CEO Tim Cahill saying that the company has "a whole number of product lines that will contribute very well, that are going to fit very well with what is necessary to achieve the mission."
Despite the developments, many have expressed serious concerns about the system's development and some experts believe the initiative could trigger a worldwide <a href="https://www.benzinga.com/general/space/25/05/45584539/donald-trumps-175-billion-golden-dome-could-trigger-a-new-space-arms-race-expert-warns-its-opening-a-pandoras-box">space-based arms race</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45548110/trumps-golden-dome-launches-new-era-for-defense-stocks-like-rtx-lockheed-martin-l3harris">Trump&#8217;s Expensive Golden Dome Launches New Era For Defense Stocks Like RTX, Lockheed Martin, L3Harris</a></li>
</ul>
Image Via Shutterstock

PLTR

US Tests Radar That Could Help Trump's Golden Dome Detect Missiles Over 1,200 Miles: Report

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Buy and maintains $16 price target.

ACRS

HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

Artificial intelligence startup, BigBear.ai Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>), has witnessed big spikes in recent weeks, as retail investors seize on rising short interest and swelling options activity to fuel speculations of a short squeeze.
Check out the current price of <a href="https://benzinga.com/quote/BBAI">BBAI stock here</a>.
What Happened: On Tuesday, shares of <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46080056/bigbear-ai-bbai-stock-soars-21-whats-going-on">BigBear rallied 25.12%</a>, ending the day at $5.23 per share, as the company announced a string of strategic partnerships and deployments over the past couple of days.
This includes its <a href="https://www.benzinga.com/pressreleases/25/06/b45972242/bigbear-ai-deploys-enhanced-passenger-processing-biometric-technology-at-major-ports-of-entry-incl">biometric ID software</a> going live across major U.S. and international airports, including JFK, LAX, and Chicago O'Hare, according to an announcement made last week. Before this, the company inked a strategic partnership with Easy Lease PJSC to accelerate its AI development and deployment in the Middle East.
BigBear has also had two major Department of Defense wins in 2025, a J-35 force management contract and a geopolitical risk prototype with the DoD&#8217;s Chief Digital and Artificial Intelligence Office.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/46089114/google-built-android-to-protect-its-ad-empire-not-ai-says-perplexitys-aravind-srinivas-says-os-must-be-reengineered-for-agentic-future">Google Built Android To Protect Its Ad Empire, Not AI, Says Perplexity&#8217;s Aravind Srinivas: Says OS Must Be Reengineered For Agentic Future</a>
All of these were key catalysts for the company, which many analysts have since dubbed &#8220;The Next Palantir,&#8221; given the remarkable similarities in their areas of focus.
However, the key reason behind recent spikes in the stock is its elevated short interest, with 22.25% <a href="https://fintel.io/ss/us/bbai">of</a> the company&#8217;s float, or approximately 65 million shares, being sold short. This is paired with a borrow fee of 4.69%, up from 3.23% two weeks ago, thus making it expensive to short the stock, and making it ripe for a short squeeze.
Options activities have similarly exploded, with over 271,000 contracts being traded on June 24 alone, with 80.97% being calls, fueling speculation that market makers could be forced to hedge by buying shares, something known as a &#8220;gamma squeeze.&#8221;
There&#8217;s also been a lot of chatter surrounding BigBear.ai&#8217;s potential short squeeze in popular Reddit communities, and this has been going on for the past several months.
<figure class="wp-block-image aligncenter size-large is-resized"><img loading="lazy" decoding="async" width="977" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25055128/Screenshot-2025-06-25-at-3.19.32-PM-977x1024.png" alt="" class="wp-image-961282" style="width:513px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25055128/Screenshot-2025-06-25-at-3.19.32-PM-977x1024.png 977w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25055128/Screenshot-2025-06-25-at-3.19.32-PM-286x300.png 286w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25055128/Screenshot-2025-06-25-at-3.19.32-PM-768x805.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25055128/Screenshot-2025-06-25-at-3.19.32-PM-1465x1536.png 1465w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25055128/Screenshot-2025-06-25-at-3.19.32-PM.png 1482w" sizes="(max-width: 977px) 100vw, 977px" /></figure>
<figure class="wp-block-image aligncenter size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="309" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25055145/Screenshot-2025-06-25-at-3.21.03-PM-1024x309.png" alt="" class="wp-image-961284" style="width:524px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25055145/Screenshot-2025-06-25-at-3.21.03-PM-1024x309.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25055145/Screenshot-2025-06-25-at-3.21.03-PM-300x90.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25055145/Screenshot-2025-06-25-at-3.21.03-PM-768x232.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25055145/Screenshot-2025-06-25-at-3.21.03-PM.png 1472w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
This was from the /r/ShortSqueeze community <a href="https://www.reddit.com/r/Shortsqueeze/comments/1g3bs3w/bbai_is_simple_short_squeeze_very_possible_if_not/">on</a> Reddit, with several other subreddits now actively discussing the stock, and its potential short squeeze over the next couple of days.
Why It Matters: Analysts maintain a <a href="https://www.benzinga.com/quote/BBAI/analyst-ratings">cautiously optimistic</a> outlook on the stock, with a consensus price target at $4.63 per share, 11.47% below its current levels.
According to The Motley Fool, BigBear is <a href="https://www.benzinga.com/markets/small-cap/25/06/45857163/the-next-palantir-does-this-under-5-ai-stock-have-the-potential-to-rise-and-shine">expected to underperform</a> for the next five years, since 40% of its revenue is tied to government contracts, which are now under threat as part of DOGE-related cutbacks. 
The company continues to disappoint on earnings, with $34.76 million in revenue <a href="https://www.benzinga.com/news/earnings/25/05/45152870/bigbear-ai-shares-slide-after-worse-than-expected-q1-report">during its first quarter</a>, missing estimates at $36.26 million, along with a loss of $0.26 per share, higher than estimates at $0.06 per share.
Price Action: Shares of BigBear.ai were up 25.12% on Tuesday, at $5.23, and are up a further 5.05% after hours, at the time of writing this.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="143" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25060237/Screenshot-2025-06-25-at-3.32.25-PM-1024x143.png" alt="" class="wp-image-961302" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25060237/Screenshot-2025-06-25-at-3.32.25-PM-1024x143.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25060237/Screenshot-2025-06-25-at-3.32.25-PM-300x42.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25060237/Screenshot-2025-06-25-at-3.32.25-PM-768x108.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25060237/Screenshot-2025-06-25-at-3.32.25-PM.png 1514w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The stock scores high on momentum, at the 98th percentile, and has a favorable price trend in the short, medium and long terms. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> for deeper insights into the stock. 
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46089330/bernie-sanders-slams-job-cuts-says-ai-should-give-workers-more-time-off-instead-of-throwing-you-out-on-the-street">Bernie Sanders Slams Job Cuts, Says AI Should Give Workers More Time Off: &#8216;Instead Of Throwing You Out On The Street&#8230;&#8217;</a></li>
</ul>
Photo courtesy: PJ McDonnell / Shutterstock.com

BBAI

BigBear.ai's Surges Over 25% Amid Defense Contracts, Airport Deployments And Short Squeeze Hype

Macro Economic Events

Econ #s

Economics

France Jobseekers Total For May 3,002.0K Vs. 3,013.0K Prior

Repurchased $225 million principal amount of convertible notes removing approximately 8.3 million underlying shares as well as approximately $63.8 million of remaining interest
Issued 9.45 million shares to participating note holders to fund the repurchase
AST SpaceMobile, Inc. ("AST SpaceMobile") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, and designed for both commercial and government applications, today announced the pricing of a cash repurchase (the "Repurchase") of $225 million aggregate principal amount of its 4.25% convertible notes due 2032 (the "2032 convertible notes") pursuant to separate, privately negotiated repurchase transactions with a limited number of holders of the 2032 convertible notes and a registered direct offering of 9,450,268 shares of its Class A common stock to holders of 2032 convertible notes participating in the Repurchase in a direct placement registered under the Securities Act of 1933, as amended (the "Registered Direct Offering").
With this series of transactions, AST SpaceMobile, Inc. will issue approximately 1.04 million incremental shares to the underlying shares of the 2032 convertible notes being repurchased while removing $225 million of debt from the balance sheet and approximately $63.8 million of remaining interest. Both the closing of the Repurchase and the Registered Direct Offering are expected to take place on or about July 1, 2025. The transactions are cross-conditional.

ASTS

AST SpaceMobile Prices Cash Repurchase Of $225M Aggregate Principal Amount Of 4.25% Convertible Notes Due 2032

HC Wainwright &amp; Co. analyst Kevin Dede initiates coverage on CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) with a Neutral rating.

Initiation

CRWV

HC Wainwright & Co. Initiates Coverage On CoreWeave with Neutral Rating

AKAM

Akamai Expands API Security With Managed Service, Code Scanning, Compliance Dashboard Amid Rising Threats And Industry Awards

HC Wainwright &amp; Co. analyst Mitchell Kapoor downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Sell and lowers the price target from $40 to $10.

Comments

Tapinator

Tapinator (TAPM) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル